Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer Corrigendum in /10.3892/ijo.2024.5694

Iida,Katsuyuki; Zheng,Rong; Shen,Ruoqian; Nanus,David  M.

doi:10.3892/ijo.2012.1586

Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer

Corrigendum in: /10.3892/ijo.2024.5694

Authors:
- Katsuyuki Iida
- Rong Zheng
- Ruoqian Shen
- David M. Nanus
View Affiliations

Affiliations: Genitourinary Oncology Research Laboratory, Department of Medicine, Weill Cornell Medical College and Weill Cornell Cancer Center, New York, NY, USA
Published online on: August 8, 2012 https://doi.org/10.3892/ijo.2012.1586
Pages: 1192-1198
Copyright: © Iida et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neutral endopeptidase (NEP) is a cell-surface peptidase that inhibits prostate cancer cell growth partly via inhibition of Akt kinase. We investigated the antitumor effects of an adenovirus gene delivery system (AdNEP) to restore NEP expression in DU145 prostate cancer cells in combination with paclitaxel chemotherapy. DU145 cells were infected with adenovirus expressing NEP or LacZ, treated with paclitaxel, and assessed for cell viability, Akt activation and induction of apoptosis. Athymic mice with established DU145 xenografts were injected intratumorally with AdNEP or AdLacZ and intraperitoneally with paclitaxel and monitored for tumor growth over 28 days. Compared to AdLacZ plus paclitaxel, AdNEP plus paclitaxel significantly inhibited DU145 cell growth and increased apoptosis as determined by increased caspase-3 and PARP-1 proteolytic fragments. In a xenograft model, tumor volume was reduced in mice treated with AdNEP plus paclitaxel (122.85±89.5 mm3; P<0.01) compared with mice treated with AdNEP plus saline (653.9±230.3 mm3), AdLacZ plus paclitaxel (575.9±176.6 mm3) or AdLacZ plus saline (920.2±238.2 mm3). In conclusion, these data suggest that NEP can augment taxane-induced apoptosis through inhibition of Akt/Bad signaling, and that the combination of NEP plus paclitaxel may be an effective strategy to inhibit castration-resistant prostate cancer growth.

View Figures

View References

1	Turner AJ: Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans. 31:723–727. 2003. View Article : Google Scholar : PubMed/NCBI
2	Maguer-Satta V, Besancon R and Bachelard-Cascales E: Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 29:389–396. 2011. View Article : Google Scholar
3	Papandreou CN, Usmani B, Geng YP, Bogenrieder T, Freeman RH, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP and Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 4:50–57. 1998. View Article : Google Scholar : PubMed/NCBI
4	Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV and Belldegrun AS: Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 55:71–80. 2003. View Article : Google Scholar : PubMed/NCBI
5	Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C and Nanus DM: Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res. 10:4096–4100. 2005. View Article : Google Scholar : PubMed/NCBI
6	Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB and Nanus DM: Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res. 6:1664–1670. 2000.PubMed/NCBI
7	Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B and Nanus DM: Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest. 106:1399–1407. 2000. View Article : Google Scholar : PubMed/NCBI
8	Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT and Nanus DM: Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res. 7:1370–1377. 2001.PubMed/NCBI
9	Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R, Georgescu MM and Nanus DM: Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 5:67–78. 2004. View Article : Google Scholar : PubMed/NCBI
10	Iwase A, Shen R, Navarro D and Nanus DM: Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem. 279:11898–11905. 2004. View Article : Google Scholar : PubMed/NCBI
11	Osman I, Dai J, Mikhail M, Navarro D, Taneja SS, Lee P, Christos P, Shen R and Nanus DM: Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer. 107:2628–2636. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sumitomo M, Asano T, Asakuma J, Asano T, Nanus DM and Hayakawa M: Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res. 10:260–266. 2004. View Article : Google Scholar : PubMed/NCBI
13	Mancuso A, Oudard S and Sternberg CN: Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol. 61:176–185. 2007. View Article : Google Scholar : PubMed/NCBI
14	Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
15	Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
16	Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S and Ma D: Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 273:257–265. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Yu D, Agrawal S and Zhang R: Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate. 54:194–205. 2003. View Article : Google Scholar : PubMed/NCBI
18	Horiguchi A, Zheng R, Goodman OB Jr, Shen R, Guan H, Hersh LB and Nanus DM: Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Ther. 14:583–589. 2007. View Article : Google Scholar : PubMed/NCBI
19	Mitsiades CS, Mitsiades N and Koutsilieris M: The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 4:235–256. 2004. View Article : Google Scholar : PubMed/NCBI
20	Horiguchi A, Chen DY, Goodman OB Jr, Zheng R, Shen R, Guan H, Hersh LB and Nanus DM: Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis. Prostate Cancer Prostatic Dis. 11:79–87. 2008. View Article : Google Scholar : PubMed/NCBI
21	De Souza PL, Russell PJ and Kearsley J: Role of the Akt pathway in prostate cancer. Curr Cancer Drug Targets. 9:163–175. 2009.PubMed/NCBI
22	Siepmann M, Kumar S, Mayer G and Walter J: Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to Akt. PLoS One. 5:e131342010. View Article : Google Scholar : PubMed/NCBI
23	Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A and Hayakawa M: ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res. 10:794–801. 2004. View Article : Google Scholar
24	Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G and Nicolin A: Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate. 67:782–789. 2007. View Article : Google Scholar : PubMed/NCBI
25	McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
26	Naghavi MH, Valente S, Hatziioannou T, de Los SK, Wen Y, Mott C, Gundersen GG and Goff SP: Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells. EMBO J. 26:41–52. 2007. View Article : Google Scholar : PubMed/NCBI
27	Haedicke J, de Los SK, Goff SP and Naghavi MH: The Ezrinradixin-moesin family member ezrin regulates stable microtubule formation and retroviral infection. J Virol. 82:4665–4670. 2008. View Article : Google Scholar : PubMed/NCBI
28	Niv MY, Iida K, Zheng R, Horiguchi A, Shen R and Nanus DM: Rational redesign of neutral endopeptidase binding to merlin and moesin proteins. Protein Sci. 18:1042–1050. 2009. View Article : Google Scholar : PubMed/NCBI
29	Terawaki S, Kitano K and Hakoshima T: Structural basis for type II membrane protein binding by ERM proteins revealed by the radixin-neutral endopeptidase 24.11 (NEP) complex. J Biol Chem. 282:19854–19862. 2007. View Article : Google Scholar : PubMed/NCBI
30	Reyland ME, Anderson SM, Matassa AA, Barzen KA and Quissell DO: Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells. J Biol Chem. 274:19115–19123. 1999. View Article : Google Scholar : PubMed/NCBI
31	Matassa AA, Carpenter L, Biden TJ, Humphries MJ and Reyland ME: PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem. 276:29719–29728. 2001. View Article : Google Scholar : PubMed/NCBI
32	Sumitomo M, Ohba M, Asakuma J, Asano T, Kuroki T, Asano T and Hayakawa M: Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J Clin Invest. 109:827–836. 2002. View Article : Google Scholar : PubMed/NCBI
33	Majumder PK, Pandey P, Sun X, Cheng K, Datta R, Saxena S, Kharbanda S and Kufe D: Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem. 275:21793–21796. 2000. View Article : Google Scholar : PubMed/NCBI
34	Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D and Nanus DM: Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. Cancer Res. 60:6590–6596. 2000.
35	Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M and Kim JH: Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther. 15:636–642. 2007.PubMed/NCBI
36	Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS and James ND: A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol Ther. 17:1292–1299. 2009. View Article : Google Scholar : PubMed/NCBI
37	Hong Y, Beckett C, Belyaev ND and Turner AJ: The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. Int J Cancer. 130:775–786. 2012. View Article : Google Scholar : PubMed/NCBI